IN THE UNITED STATES PATENT AND TRADEMARK OFFICE UL 17 2002

atent Application of

Zongxuan JIN et al.

Group Art Unit: 1614

Serial No. 09/863,316

Examiner: D. Jagoe

Filed: May 24, 2001

For: SKIN CANCER PREVENTIVE AGENT

Commissioner of Patents Washington, DC 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

No additional fee is required.

The fee has been calculated as shown below

CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	8	MINUS	4	=0	x \$9 \$18	\$0.00
INDEP. CLAIMS	2	MINUS	1	=0	x\$40 \$84	\$0.00
Fee for Multiple Dependent Claims \$130/\$260						
			TOTAL ADDITIONAL FEE FOR THIS AMEND-MENT		\$0.00	

- If the entry in Column 2 is less than the entry in Column 4,
- write "0" in Column 5.
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The Commissioner is authorized to charge \$400.00 for a 2-month extension of time to GOT-0011

The Commissioner is hereby authorized to charge any additional fees incurred to this application, or to credit any overpayment, to Deposit Account No. 18-0013. A duplicate Deposit Account No. 18-0013. \boxtimes \boxtimes

Applicant's undersigned attorney may be reached by telephone in our Washington D.C. copy of this sheet is enclosed. Ø

Office at

(202) 955-3750.

All correspondence should be directed to our below listed address.

Date: July 12, 2002

David K. Benson Reg. No. 42,314

RADER, FISHMAN & GRAUER PLLC 1233 20TH Street, NW

Suite 501

Washington, DC 20036

Telephone: (202) 955-3750 Facsimile: (202) 955-3751

Customer No. 23353

DKB/nb

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Patent Application of

JUL 12 2002 🔀 ngxuan JIN et al.

erial No. 09/863,316

Filed: May 24, 2001

For: SKIN CANCER PREVENTIVE AGENT

Group Art Unit:

Examiner: D. Jagoe

AMENDMENT

Commissioner of Patents Washington, DC 20231

Sir:

In response to the non-final Official Action mailed on February 12, 2002 (Paper No. 3), please amend the aboveidentified application as follows:

IN THE CLAIMS:

Please cancel claims 1 to 4. Please add new claims 5 to 12 as shown in the Appendix, and as presented immediately herebelow.

31 5. (New) A method of inhibiting skin cancer in a mammal, comprising the step of administering to the mammal a composition comprised of sericin.